| Sun, Lingyun |
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease |
|
|
| Recruiting | 3 | 440 | Europe, Japan, US, RoW | Belimumab, BENLYSTA, GSK1550188, Placebo | GlaxoSmithKline | Lung Diseases, Interstitial | 10/28 | 12/28 | | |
NCT06716606: A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease |
|
|
| Recruiting | 3 | 225 | RoW | Belimumab | GlaxoSmithKline, ICON plc | Bronchial Diseases | 08/28 | 01/30 | | |
| Recruiting | 2/3 | 240 | Europe, Canada, Japan, US, RoW | EFG PH20 SC, PBO | argenx, argenx BV | Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome | 12/26 | 02/27 | | |
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease |
|
|
| Recruiting | 2/3 | 300 | Europe, Japan, US, RoW | Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo | GlaxoSmithKline | Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic | 07/27 | 07/27 | | |
|
NCT04830644: A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome. |
|
|
| Recruiting | 2 | 144 | RoW | Iguratimod, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Primary Sjögren Syndrome | 04/22 | 06/22 | | |
NCT06222671: A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA) |
|
|
| Not yet recruiting | 2 | 180 | RoW | 608, Placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Axial Spondyloarthritis | 11/25 | 11/25 | | |
NCT05849727: A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis |
|
|
| Recruiting | 2 | 180 | RoW | TQH3821 tablets 200 mg, TQH3821 tablets matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Rheumatoid Arthritis | 06/24 | 12/24 | | |
| Completed | 2 | 456 | Europe, Japan, US, RoW | Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Systemic Lupus Erythematosus | 11/24 | 11/24 | | |
|
|
NCT06058078: RY_SW01 Cell Injection Therapy in Active Lupus Nephritis |
|
|
| Recruiting | 2 | 60 | RoW | RY_SW01 cell injection, UC-MSC treatment, Basic treatment, Immunosuppressive drugs | Jiangsu Renocell Biotech Company, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Lupus Nephritis | 12/25 | 12/28 | | |
NCT06717815: Phase Ib/IIa Study for IPG11406 in Patients with Lupus Nephritis |
|
|
| Not yet recruiting | 1/2 | 36 | RoW | IPG11406 | Nanjing Immunophage Biotech Co., Ltd | Lupus Nephritis | 11/25 | 04/26 | | |
NCT04457856: A Study of TJ003234 in Rheumatoid Arthritis Patients |
|
|
| Recruiting | 1 | 63 | RoW | TJ003234 injection | I-Mab Biopharma Co. Ltd. | Rheumatoid Arthritis | 03/23 | 03/23 | | |
NCT06340490: A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE) |
|
|
| Not yet recruiting | 1 | 24 | RoW | RJMty19 (CD19-CAR-DNT cells), Fludarabine, Cyclophosphamide | Guangdong Ruishun Biotech Co., Ltd, RenJi Hospital, Peking University People's Hospital, Changhai Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Systemic Lupus Erythematosus | 12/26 | 12/27 | | |
| Wei, Wei |
NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3 |
|
|
| Recruiting | 4 | 466 | RoW | Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638 | The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd. | Renal Insufficiency, Chronic | 10/25 | 03/26 | | |
NCT05439629: Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | BAT5906 injection, Lucentis | Bio-Thera Solutions | Neovascular (Wet) Age-related Macular Degeneration | 04/24 | 06/25 | | |
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease |
|
|
| Recruiting | 3 | 440 | Europe, Japan, US, RoW | Belimumab, BENLYSTA, GSK1550188, Placebo | GlaxoSmithKline | Lung Diseases, Interstitial | 10/28 | 12/28 | | |
| Recruiting | 2/3 | 240 | Europe, Canada, Japan, US, RoW | EFG PH20 SC, PBO | argenx, argenx BV | Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome | 12/26 | 02/27 | | |
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus |
|
|
| Recruiting | 2 | 186 | RoW | Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Systemic Lupus Erythematosus, SLE | 08/25 | 05/26 | | |
NCT05849727: A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis |
|
|
| Recruiting | 2 | 180 | RoW | TQH3821 tablets 200 mg, TQH3821 tablets matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Rheumatoid Arthritis | 06/24 | 12/24 | | |
| Completed | 2 | 456 | Europe, Japan, US, RoW | Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Systemic Lupus Erythematosus | 11/24 | 11/24 | | |
|
|
| Completed | 1/2 | 60 | RoW | 2.5mg of BAT5906, 4.0mg of BAT5906 | Bio-Thera Solutions | Diabetic Macular Edema | 11/23 | 11/23 | | |
NCT05247203: Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus |
|
|
| Completed | 1 | 92 | RoW | Telitacicept, RC18, standard therapy | RemeGen Co., Ltd. | Systemic Lupus Erythematosus | 10/23 | 11/23 | | |
| Lu, Liangjing |
| Completed | 2 | 456 | Europe, Japan, US, RoW | Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Systemic Lupus Erythematosus | 11/24 | 11/24 | | |
|
|
NCT06414135: Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis |
|
|
| Recruiting | 1 | 6 | RoW | Relma-cel | Liangjing Lu, Shanghai Ming Ju Biotechnology Co., Ltd. | Systemic Sclerosis | 05/25 | 04/27 | | |
NCT06567080: JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases |
|
|
| Not yet recruiting | 1 | 15 | RoW | JWCAR201 | RenJi Hospital, Shanghai Ming Ju Biotechnology Co., Ltd. | B-cell Tumors, Autoimmune Diseases, Lupus Erythematosus, Systemic, Large B-cell Lymphoma | 09/25 | 03/27 | | |
| Wytyk-Nowak, Agata |
RESOLUTION-1, NCT05516758: A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis |
|
|
| Completed | 2 | 491 | Europe, Canada, Japan, US, RoW | Peresolimab, Placebo | Eli Lilly and Company | Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases | 11/23 | 01/25 | | |
NCT05123586: A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus |
|
|
| Terminated | 2 | 85 | Europe, US, RoW | LY3361237, Placebo | Eli Lilly and Company | Systemic Lupus Erythematosus | 12/23 | 12/23 | | |
| Completed | 2 | 456 | Europe, Japan, US, RoW | Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Systemic Lupus Erythematosus | 11/24 | 11/24 | | |
|
|
